nsc 181928 has been researched along with Experimental Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamson, DJ; Bowdon, BJ; Temple, CG; Werline, JA; Wheeler, GP | 1 |
1 other study(ies) available for nsc 181928 and Experimental Neoplasms
| Article | Year |
|---|---|
Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,2-dihydro-3-[(N-methylanilino)methyl]-pyrido[3,4-b]pyrazin-7-ylcarbamate (NSC 181928).
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; Cell Survival; DNA; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Methotrexate; Mice; Mice, Inbred BALB C; Mitosis; Neoplasm Transplantation; Neoplasms, Experimental; Pyrazines | 1982 |